Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3
Cell-mediated immune responses to hepatitis C virus (HCV) proteins play a key role in recovery from infection. The NS3 protein of HCV is of special interest, since it is one of the most conserved proteins and NS3-specific immune responses are stronger and more frequently observed in patients resolving the infection than in chronically infected patients. Since these characteristics make NS3 an attractive vaccine candidate, the objective of this study was to optimize NS3-specific immune responses. Results from this group first demonstrated that a plasmid enriched with 24 CpG motifs (pBISIA24-NS3) tends to induce the strongest and most consistent Th1-biased immune response. Subsequently, it was shown that NS3 formulated with CpG oligodeoxynucleotide and Quil A (rNS3+CpG+Quil A) adjuvants induces a balanced immune response in mice, whereas rNS3 combined with either CpG or Quil A elicits a Th2-biased response. To further enhance NS3-specific cell-mediated immune responses, a vaccination regime consisting of priming with pBISIA24-NS3, followed by boosting with rNS3+CpG+Quil A, was explored in mice and pigs. When compared to immunization with rNS3+CpG+Quil A, this regime shifted the immune response to a Th1-type response and, accordingly, enhanced MHC I-restricted killing by cytotoxic T lymphocytes in mice. Although immunization with pBISIA24-NS3 also induced a Th1-biased response, including cytotoxicity in the mice, the humoral response was significantly lower than that induced by the DNA prime–protein boost regime. These results demonstrate the advantage of a DNA prime–protein boost approach in inducing a strong NS3-specific cell-mediated, as well as humoral, immune response, in both inbred laboratory and outbred large animal species.
AnwerK.,
EarleK. A.,
ShiM.11 other authors1999; Synergistic effect of formulated plasmid and needle-free injection for genetic vaccines. Pharm Res 16:889–895[CrossRef]
Baca-EstradaM. E.,
SniderM.,
TikooS. K.,
HarlandR.,
BabiukL. A.,
van Drunen Littel-van den HurkS.1996; Immunogenicity of bovine herpesvirus 1 glycoprotein D in mice: effect of antigen form on the induction of cellular and humoral immune responses. Viral Immunol 9:11–22[CrossRef]
BattegayM.,
FikesJ.,
Di BisceglieA. M.11 other authors1995; Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2·1 molecules. J Virol 69:2462–2470
BoyerJ. D.,
WangB.,
UgenK. E.9 other authors1996; In vivo protective anti-HIV immune responses in non-human primates through DNA immunization. J Med Primatol 25:242–250[CrossRef]
BrinsterC.,
ChenM.,
BoucreuxD.,
Paranhos-BaccalaG.,
LiljestromP.,
LemmonierF.,
InchauspeG.2002; Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J Gen Virol 83:369–381
BryanL. A.,
GriebelP. J.,
HainesD. M.,
DavisW. C.,
AllenJ. R.1988; Immunocytochemical identification of bovine Langerhans cells by use of a monoclonal antibody directed against class II MHC antigens. J Histochem Cytochem 36:991–995[CrossRef]
BukhJ.,
FornsX.,
EmersonS. U.,
PurcellR. H.2001; Studies of hepatitis C virus in chimpanzees and their importance for vaccine development. Intervirology 44:132–142[CrossRef]
ChooQ. L.,
KuoG.,
RalstonR.15 other authors1994; Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A 91:1294–1298[CrossRef]
ChuR. S.,
TargoniO. S.,
KriegA. M.,
LehmannP. V.,
HardingC. V.1997; CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186:1623–1631[CrossRef]
DavisH. L.,
WeeratnaR.,
WaldschmidtT. J.,
TygrettL.,
SchorrJ.,
KriegA. M.1998; CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160:870–876
DavisH. L.,
SupartoI. I.,
WeeratnaR. R.10 other authors2000; CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 18:1920–1924[CrossRef]
DiepolderH. M.,
GerlachJ. T.,
ZachovalR.9 other authors1997; Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 71:6011–6019
DonnellyJ. J.,
FriedmanA.,
MartinezD.,
MontgomeryD. L.,
ShiverJ. W.,
MotzelS. L.,
UlmerJ. B.,
LiuM. A.1995; Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1:583–587[CrossRef]
Duenas-CarreraS.,
VinaA.,
MartinezR.7 other authors2004; Immunization with a DNA vaccine encoding the hepatitis-C-virus structural antigens elicits a specific immune response against the capsid and envelope proteins in rabbits and Mecaca irus (crab-eating macaque monkeys. Biotechnol Appl Biochem 39:249–255[CrossRef]
EnckeJ.,
zu PutlitzJ.,
GeisslerM.,
WandsJ. R.1998; Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J Immunol 161:4917–4923
FarciP.,
AlterH. J.,
WongD. C.,
MillerR. H.,
GovindarajanS.,
EngleR.,
ShapiroM.,
PurcellR. H.1994; Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 91:7792–7796[CrossRef]
FynanE. F.,
WebsterR. G.,
FullerD. H.,
HaynesJ. R.,
SantoroJ. C.,
RobinsonH. L.1993; DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A 90:11478–11482[CrossRef]
GeisslerM.,
GesienA.,
TokushigeK.,
WandsJ. R.1997; Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol 158:1231–1237
GrakouiA.,
WychowskiC.,
LinC.,
FeinstoneS. M.,
RiceC. M.1993; Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 67:1385–1395
HartmannG.,
WeeratnaR. D.,
BallasZ. K.9 other authors2000; Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 164:1617–1624[CrossRef]
HijikataM.,
KatoN.,
OotsuyamaY.,
NakagawaM.,
ShimotohnoK.1991; Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci U S A 88:5547–5551[CrossRef]
IoannouX. P.,
GriebelP.,
HeckerR.,
BabiukL. A.,
van Drunen Littel-van den HurkS.2002a; The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J Virol 76:9002–9010[CrossRef]
IoannouX. P.,
GomisS. M.,
KarvonenB.,
HeckerR.,
BabiukL. A.,
van Drunen Littel-van den HurkS.2002b; CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine 21:127–137[CrossRef]
IoannouX. P.,
GriebelP.,
MenaA.,
GomisS. M.,
GodsonD. L.,
MutwiriG.,
HeckerR.,
BabiukL. A.,
van Drunen Littel-van den HurkS.2003; Safety of CpG oligodeoxynucleotides in veterinary species. Antisense Nucleic Acid Drug Dev 13:157–167[CrossRef]
JiaoX.,
WangR. Y.,
FengZ.,
AlterH. J.,
ShihJ. W.2003; Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization. Hepatology 37:452–460[CrossRef]
JinL.,
PetersonD. L.1995; Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA helicase. Arch Biochem Biophys 323:47–53[CrossRef]
KimJ. J.,
YangJ. S.,
MansonK. H.,
WeinerD. B.2001; Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants. Vaccine 19:2496–2505[CrossRef]
KurokohchiK.,
AkatsukaT.,
PendletonC. D.,
TakamizawaA.,
NishiokaM.,
BattegayM.,
FeinstoneS. M.,
BerzofskyJ. A.1996; Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region. J Virol 70:232–240
LazdinaU.,
HultgrenC.,
FrelinL. 8 other authors; 2001; Humoral and CD4+ T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein. J Gen Virol 82:1299–1308
LewisP. J.,
van Drunen Littel-van den HurkS.,
BabiukL. A.1999; Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response. J Virol 73:10214–10223
PancholiP.,
PerkusM.,
TricocheN.,
LiuQ.,
PrinceA. M.2003; DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV–vaccinia virus infection in HLA-A2.1-transgenic mice. J Virol 77:382–390[CrossRef]
PontarolloR. A.,
BabiukL. A.,
HeckerR.,
Van Drunen Littel-Van Den HurkS.2002; Augmentation of cellular immune responses to bovine herpesvirus-1 glycoprotein D by vaccination with CpG-enhanced plasmid vectors. J Gen Virol 83:2973–2981
PoynardT.,
MarcellinP.,
LeeS. S.8 other authors1998; Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352:1426–1432[CrossRef]
RankinR.,
PontarolloR.,
IoannouX.,
KriegA. M.,
HeckerR.,
BabiukL. A.,
van Drunen Littel-van den HurkS.2001; CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev 11:333–340[CrossRef]
RankinR.,
PontarolloR.,
GomisS.7 other authors2002; CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D. Vaccine 20:3014–3022[CrossRef]
RazE.,
TigheH.,
SatoY.,
CorrM.,
DudlerJ. A.,
RomanM.,
SwainS. L.,
SpiegelbergH. L.,
CarsonD. A.1996; Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci U S A 93:5141–5145[CrossRef]
SaitoI.,
MiyamuraT.,
OhbayashiA.10 other authors1990; Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 87:6547–6549[CrossRef]
SamaniT. D.,
JollesB.,
LaigleA.2001; Best minimally modified antisense oligonucleotides according to cell nuclease activity. Antisense Nucleic Acid Drug Dev 11:129–136[CrossRef]
ShimizuY. K.,
FeinstoneS. M.,
KoharaM.,
PurcellR. H.,
YoshikuraH.1996; Hepatitis C virus: detection of intracellular virus particles by electron microscopy. Hepatology 23:205–209[CrossRef]
SongM. K.,
LeeS. W.,
SuhY. S.,
LeeK. J.,
SungY. C.2000; Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice. J Virol 74:2920–2925[CrossRef]
StittelaarK. J.,
BoesJ.,
KerstenG. F.8 other authors2000; In vivo antibody response and in vitro CTL activation induced by selected measles vaccine candidates, prepared with purified Quil A components. Vaccine 18:2482–2493[CrossRef]
TakakiA.,
WieseM.,
MaertensG.,
DeplaE.,
SeifertU.,
LiebetrauA.,
MillerJ. L.,
MannsM. P.,
RehermannB.2000; Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6:578–582[CrossRef]
TedeschiV.,
AkatsukaT.,
ShihJ. W.,
BattegayM.,
FeinstoneS. M.1997; A specific antibody response to HCV E2 elicited in mice by intramuscular inoculation of plasmid DNA containing coding sequences for E2. Hepatology 25:459–462[CrossRef]
ThimmeR.,
OldachD.,
ChangK. M.,
SteigerC.,
RayS. C.,
ChisariF. V.2001; Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194:1395–1406[CrossRef]
UlmerJ. B.,
DonnellyJ. J.,
ParkerS. E.7 other authors1993; Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745–1749[CrossRef]
Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3